Samalizumab
Modify Date: 2024-01-02 20:49:39
Samalizumab structure
|
Common Name | Samalizumab | ||
|---|---|---|---|---|
| CAS Number | 1073059-33-2 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of SamalizumabSamalizumab (ALXN 6000) is a humanized monoclonal antibody that specifically binds to CD200 and blocks its ligation to the CD200 receptor (CD200R). Samalizumab can be used for multiple myeloma and B-cell chronic lymphocytic leukemia research[1]. |
| Name | Samalizumab |
|---|
| Description | Samalizumab (ALXN 6000) is a humanized monoclonal antibody that specifically binds to CD200 and blocks its ligation to the CD200 receptor (CD200R). Samalizumab can be used for multiple myeloma and B-cell chronic lymphocytic leukemia research[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Samalizumab 被合理设计为具有 Ig G2/G4 恒定区，以最大限度地减少效应子功能并保护免疫细胞亚群。Samalizumab 是一种重组人源化抗 CD200 单抗，旨在消除效应子功能，特异性结合免疫检查点 CD200，阻断受体参与和信号传导，并拮抗 CD200 驱动的免疫抑制，从而发挥抗肿瘤作用免疫反应[1]。 |
| References |
| No Any Chemical & Physical Properties |